MOONLAKE IMMUNOTHERAPEUTICS
MLTXNASDAQ🏆 #2504 by market capEarnings Nov 4US Equity
$11.45▼ $0.11 (−0.95%)
🌙 After hours$11.45▲ 0.00%Regular close · extended-hours price shownTrack MLTX
Get earnings, price moves & breaking news on Telegram
24h▼ 0.9%
7d▼ 11.2%
14d▼ 8.3%
30d▼ 23.9%
ytd▼ 13.0%
1y▲ 59.7%
🏦Market Cap
$963M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
MOONLAKE IMMUNOTHERAPEUTICS
MLTXAnalyst Ratings
Price
$11.45
Total
19
Raised
2
Lowered
2
Avg PT
$50.00
H / L
$50 / $50
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-08-13 | — | — |
Leerink Partners | Reiterated | Outperform | 2026-07-01 | — | — |
BTIG | Reiterated | Buy | 2026-06-09 | — | — |
Needham | Reiterated | Buy | 2026-05-12 | $20.00 | +74.70% |
Wolfe Research | Upgraded | Underperform → Outperform | 2026-03-23 | — | — |
Rothschild & Co | Upgraded | Neutral → Buy | 2026-03-19 | — | — |
Clear Street | Reiterated | Buy | 2026-03-11 | — | — |
RBC Capital | Reiterated | Sector Perform | 2026-03-02 | $10.00 | −12.70% |
Oppenheimer | Reiterated | Outperform | 2026-02-24 | $35.00 | +205.70% |
Goldman Sachs | Downgraded | Neutral → Sell | 2026-01-15 | $10.00 | −12.70% |
Citigroup | Downgraded | Neutral → Sell | 2025-10-29 | — | — |
Guggenheim | Reiterated | Buy | 2025-09-30 | $20.00 | +74.70% |
Wedbush | Reiterated | Outperform | 2025-09-30 | — | — |
Stifel | Reiterated | Buy | 2023-12-18 | — | — |
Cantor Fitzgerald | Reiterated | Overweight | 2023-11-08 | — | — |
Barclays | Reiterated | Equal Weight | 2023-09-12 | — | — |
Jefferies | Reiterated | Buy | 2022-11-11 | $8.00 | −30.10% |
SVB Leerink | Reiterated | Outperform | 2022-08-25 | — | — |
Cowen & Co. | Reiterated | Outperform | 2022-07-07 | — | — |
Institution
HC Wainwright & Co.
Reiterated · Buy · 2026-08-13
—
—
Leerink Partners
Reiterated · Outperform · 2026-07-01
—
—
BTIG
Reiterated · Buy · 2026-06-09
—
—
Needham
Reiterated · Buy · 2026-05-12
$20.00
+74.70%
Wolfe Research
Upgraded · Underperform → Outperform · 2026-03-23
—
—
Rothschild & Co
Upgraded · Neutral → Buy · 2026-03-19
—
—
Clear Street
Reiterated · Buy · 2026-03-11
—
—
RBC Capital
Reiterated · Sector Perform · 2026-03-02
$10.00
−12.70%
Oppenheimer
Reiterated · Outperform · 2026-02-24
$35.00
+205.70%
Goldman Sachs
Downgraded · Neutral → Sell · 2026-01-15
$10.00
−12.70%
Citigroup
Downgraded · Neutral → Sell · 2025-10-29
—
—
Guggenheim
Reiterated · Buy · 2025-09-30
$20.00
+74.70%
Wedbush
Reiterated · Outperform · 2025-09-30
—
—
Stifel
Reiterated · Buy · 2023-12-18
—
—
Cantor Fitzgerald
Reiterated · Overweight · 2023-11-08
—
—
Barclays
Reiterated · Equal Weight · 2023-09-12
—
—
Jefferies
Reiterated · Buy · 2022-11-11
$8.00
−30.10%
SVB Leerink
Reiterated · Outperform · 2022-08-25
—
—
Cowen & Co.
Reiterated · Outperform · 2022-07-07
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space